The HRN™ Mouse

The Hepatic Reductase Null (HRN™ ) mouse

The HRN™ mouse lacks cytochrome P450 activity in the liver and thus provides an elegant tool for determining the role of hepatic P450 metabolism in drug disposition in vivo.

More rapid

A single bioavailability study using the HRN™ mouse can provide information as to whether a test compound is metabolised by cytochrome P450s and whether parent or metabolite is responsible for efficacy or toxicity. The model provides a means for establishing in vivo activity in the absence of first pass metabolism. Further, this model can be crossed into disease models to facilitate a concomitant evaluation of pharmacological action and drug metabolism.

More informative

This model facilitates determination of phase II drug metabolism and identifies the importance of extrahepatic metabolism in drug disposition. The HRN has uniquely advantages in toxicokinetic studies, in correlating drug dose with pharmacological effects and/or toxicity, and can also be used to determine the optimal route of administration.The HRN™ mouse has many applications in drug discovery and development:

EXAMPLE APPLICATIONS - CLICK HERE

Determination of the role of hepatic metabolism in drug disposition, efficacy, and toxicity, of test compounds in a single experiment.
Evaluation of the in vivo pharmacological potency of molecules without first pass metabolism.
Quick determination of the significance of extrahepatic drug metabolism.
Assessment of the role of Phase II drug metabolism in drug disposition.
Evaluation of the role of drug transporters in drug uptake and efflux.
Determination of whether an active metabolite is responsible for the in vivo pharmacological action.